Update on vaccines for high-risk melanoma

Sarah A. Weiss, Sunandana Chandra, Anna C. Pavlick*

*Corresponding author for this work

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The management of high-risk melanoma has historically included primary surgical resection with or without lymphadenectomy followed by an array of adjuvant options including radiation therapy or immunomodulatory therapies such as interferon-α, granulocyte macrophage colony-stimulating factor, and a multitude of vaccines. There has been a long-standing interest in the development of vaccines in high-risk and metastatic melanoma, and clinical trials have been ongoing for decades. Given that melanoma is identified as one of the most immunogenic solid tumors, there is continued hope that vaccine therapies will improve clinical outcomes. Despite intense interest in this field, few clinical trials to-date have demonstrated significant benefit from melanoma vaccines in high-risk disease. Several trials have even documented a detrimental effect on outcomes after vaccine administration. While the role of vaccines in the adjuvant setting of high-risk melanoma presently remains unclear, recent advances in immunotherapy for melanoma including development of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) monoclonal antibodies have demonstrated meaningful clinical responses. With further study and focus on mechanisms of immune regulation, there remains promise for the role of vaccines in combination with other immune-stimulatory agents in high-risk melanoma.

Original languageEnglish (US)
Pages (from-to)269-280
Number of pages12
JournalCurrent treatment options in oncology
Volume15
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Melanoma
Vaccines
Clinical Trials
CTLA-4 Antigen
Combined Vaccines
Active Immunotherapy
Immunomodulation
Risk Management
Granulocyte-Macrophage Colony-Stimulating Factor
Lymph Node Excision
Immunotherapy
Interferons
Cell Death
Radiotherapy
Monoclonal Antibodies
Neoplasms

Keywords

  • Adjuvant treatment
  • High-risk
  • Melanoma
  • Tumor-associated antigens
  • Vaccines

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Weiss, Sarah A. ; Chandra, Sunandana ; Pavlick, Anna C. / Update on vaccines for high-risk melanoma. In: Current treatment options in oncology. 2014 ; Vol. 15, No. 2. pp. 269-280.
@article{f8d93ad694314527b755bb41a443e8b1,
title = "Update on vaccines for high-risk melanoma",
abstract = "The management of high-risk melanoma has historically included primary surgical resection with or without lymphadenectomy followed by an array of adjuvant options including radiation therapy or immunomodulatory therapies such as interferon-α, granulocyte macrophage colony-stimulating factor, and a multitude of vaccines. There has been a long-standing interest in the development of vaccines in high-risk and metastatic melanoma, and clinical trials have been ongoing for decades. Given that melanoma is identified as one of the most immunogenic solid tumors, there is continued hope that vaccine therapies will improve clinical outcomes. Despite intense interest in this field, few clinical trials to-date have demonstrated significant benefit from melanoma vaccines in high-risk disease. Several trials have even documented a detrimental effect on outcomes after vaccine administration. While the role of vaccines in the adjuvant setting of high-risk melanoma presently remains unclear, recent advances in immunotherapy for melanoma including development of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) monoclonal antibodies have demonstrated meaningful clinical responses. With further study and focus on mechanisms of immune regulation, there remains promise for the role of vaccines in combination with other immune-stimulatory agents in high-risk melanoma.",
keywords = "Adjuvant treatment, High-risk, Melanoma, Tumor-associated antigens, Vaccines",
author = "Weiss, {Sarah A.} and Sunandana Chandra and Pavlick, {Anna C.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11864-014-0283-7",
language = "English (US)",
volume = "15",
pages = "269--280",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "2",

}

Update on vaccines for high-risk melanoma. / Weiss, Sarah A.; Chandra, Sunandana; Pavlick, Anna C.

In: Current treatment options in oncology, Vol. 15, No. 2, 01.01.2014, p. 269-280.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Update on vaccines for high-risk melanoma

AU - Weiss, Sarah A.

AU - Chandra, Sunandana

AU - Pavlick, Anna C.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The management of high-risk melanoma has historically included primary surgical resection with or without lymphadenectomy followed by an array of adjuvant options including radiation therapy or immunomodulatory therapies such as interferon-α, granulocyte macrophage colony-stimulating factor, and a multitude of vaccines. There has been a long-standing interest in the development of vaccines in high-risk and metastatic melanoma, and clinical trials have been ongoing for decades. Given that melanoma is identified as one of the most immunogenic solid tumors, there is continued hope that vaccine therapies will improve clinical outcomes. Despite intense interest in this field, few clinical trials to-date have demonstrated significant benefit from melanoma vaccines in high-risk disease. Several trials have even documented a detrimental effect on outcomes after vaccine administration. While the role of vaccines in the adjuvant setting of high-risk melanoma presently remains unclear, recent advances in immunotherapy for melanoma including development of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) monoclonal antibodies have demonstrated meaningful clinical responses. With further study and focus on mechanisms of immune regulation, there remains promise for the role of vaccines in combination with other immune-stimulatory agents in high-risk melanoma.

AB - The management of high-risk melanoma has historically included primary surgical resection with or without lymphadenectomy followed by an array of adjuvant options including radiation therapy or immunomodulatory therapies such as interferon-α, granulocyte macrophage colony-stimulating factor, and a multitude of vaccines. There has been a long-standing interest in the development of vaccines in high-risk and metastatic melanoma, and clinical trials have been ongoing for decades. Given that melanoma is identified as one of the most immunogenic solid tumors, there is continued hope that vaccine therapies will improve clinical outcomes. Despite intense interest in this field, few clinical trials to-date have demonstrated significant benefit from melanoma vaccines in high-risk disease. Several trials have even documented a detrimental effect on outcomes after vaccine administration. While the role of vaccines in the adjuvant setting of high-risk melanoma presently remains unclear, recent advances in immunotherapy for melanoma including development of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) monoclonal antibodies have demonstrated meaningful clinical responses. With further study and focus on mechanisms of immune regulation, there remains promise for the role of vaccines in combination with other immune-stimulatory agents in high-risk melanoma.

KW - Adjuvant treatment

KW - High-risk

KW - Melanoma

KW - Tumor-associated antigens

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84902373189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902373189&partnerID=8YFLogxK

U2 - 10.1007/s11864-014-0283-7

DO - 10.1007/s11864-014-0283-7

M3 - Review article

C2 - 24788575

AN - SCOPUS:84902373189

VL - 15

SP - 269

EP - 280

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 2

ER -